https://www.selleckchem.com/products/ala-gln.html
We utilized local data, including National Health Insurance claims data, national statistics, literature and expert surveys with haematologists. Base-case analysis results showed that compared with BPA-OD, lifetime emicizumab prophylaxis prevented 807 bleedings, extended 3.04 quality-adjusted life-years and reduced costs by 2.6 million US dollars. Thus, emicizumab prophylaxis is a dominant treatment option with better effectiveness and lower costs than BPA-OD. A series of one-way sensitivity analyses consistently showed dominant results
Like
Comment
Share
